van Delft J H, Bergmans A, van Dam F J, Tates A D, Howard L, Winton D J, Baan R A
TNO Nutrition and Food Research Institute, Zeist, Netherlands.
Mutat Res. 1998 Jul 8;415(1-2):85-96. doi: 10.1016/s1383-5718(98)00063-1.
Comparison of results derived from transgenic animal gene-mutation assays with those from mutation analyses in endogenous genes is an important step in the validation of the former. We have used lambda lacZ transgenic mice to study alkylation-induced mutagenesis in vivo in (a) lacZ and hprt in spleen cells, and (b) lacZ and Dlb-I in small intestine from lambda lacZ+/0/Dlb-Ia/b mice. Induction of mutations by ethyl- and methylnitrosourea (ENU, MNU) and ethyl methanesulphonate (EMS) was investigated at 7 weeks after a single i.p. dose of each of these chemicals. In the small intestine, treatment with various dosages of ENU (10-150 mg/kg) resulted in a linear dose-response in both lacZ and Dlb-I. MNU (30 mg/kg) was also mutagenic in lacZ and Dlb-I, while EMS (250 mg/kg) did not significantly induce mutations in either gene. In spleen, ENU gave a linear dose-related response in both lacZ and hprt, MNU induced mutation sin both lacZ and hprt, and EMS was only positive for lacZ. No differences in response were observed between single and split-dose treatment with ENU (1 x 50 or 5 x 10 mg/kg with a 1- or 7-day interval), both in spleen and small intestine, except for lacZ in small intestine, where the single high dose gave a significantly higher induction than the split dose with the 7-day interval. The overall results suggest that mutagenic effects of fractionated doses are generally additive. In most cases, the induction factor (ratio treated over controls) for mutations in lacZ was lower than that for hprt and Dlb-I, presumably due to a higher background in lacZ and/or a lower mutability of lacZ. The general concordance between the data for lacZ and the endogenous genes indicates that lambda lacZ transgenic mice are a suitable model to study induction of gene mutations in vivo.
将转基因动物基因突变试验所得结果与内源基因的突变分析结果进行比较,是验证前者的重要一步。我们已使用λlacZ转基因小鼠研究体内烷基化诱导的诱变作用,具体如下:(a)脾脏细胞中的lacZ和hprt;(b)λlacZ+/0/Dlb-Ia/b小鼠小肠中的lacZ和Dlb-I。在单次腹腔注射每种化学物质7周后,研究了乙基亚硝基脲(ENU)、甲基亚硝基脲(MNU)和甲磺酸乙酯(EMS)诱导的突变情况。在小肠中,用不同剂量的ENU(10 - 150 mg/kg)处理后,lacZ和Dlb-I均呈现线性剂量反应。MNU(30 mg/kg)对lacZ和Dlb-I也具有诱变作用,而EMS(250 mg/kg)在这两个基因中均未显著诱导突变。在脾脏中,ENU在lacZ和hprt中均呈现线性剂量相关反应,MNU在lacZ和hprt中均诱导了突变,而EMS仅对lacZ呈阳性反应。在脾脏和小肠中,ENU单次给药(1×50或5×10 mg/kg,间隔1天或7天)与分次给药之间未观察到反应差异,但小肠中的lacZ除外,单次高剂量给药的诱导作用明显高于间隔7天的分次给药。总体结果表明,分次剂量的诱变作用通常具有累加性。在大多数情况下,lacZ基因突变的诱导因子(处理组与对照组的比值)低于hprt和Dlb-I,这可能是由于lacZ的背景较高和/或lacZ的可突变性较低。lacZ数据与内源基因数据之间的总体一致性表明,λlacZ转基因小鼠是研究体内基因突变诱导的合适模型。